Skip to main content Skip to navigation
FITC Mouse Anti-Human CD317 (BST2)
FITC Mouse Anti-Human CD317 (BST2)
Multiparameter flow cytometric analysis of CD317 (BST2) expression on Human peripheral blood leucocyte populations. Human whole blood was stained with either FITC Mouse IgG2a, κ Isotype Control (Cat. No. 553456/554647; Left Plot) or FITC Mouse Anti-Human CD317 (BST2) antibody (Cat. No. 567999/568000; Right Plot). Erythrocytes were lysed with BD FACS Lysing™ Solution (Cat. No. 349202). The pseudocolor density plot showing the correlated expression of CD317 (BST2) [or Ig Isotype control staining] versus side light-scatter (SSC-A) signals was derived from gated events with the forward and side light-scatter characteristics of intact leucocyte populations. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software.
FITC Mouse Anti-Human CD317 (BST2)
Multiparameter flow cytometric analysis of CD317 (BST2) expression on Rhesus peripheral blood leucocyte populations. Rhesus whole blood was stained with either FITC Mouse IgG2a, κ Isotype Control (Cat. No. 553456/554647; Left Plot) or FITC Mouse Anti-Human CD317 (BST2) antibody (Cat. No. 567999/568000; Right Plot). Erythrocytes were lysed with BD FACS Lysing™ Solution (Cat. No. 349202). The pseudocolor density plot showing the correlated expression of CD317 (BST2) [or Ig Isotype control staining] versus side light-scatter (SSC-A) signals was derived from gated events with the forward and side light-scatter characteristics of intact leucocyte populations. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software.
Multiparameter flow cytometric analysis of CD317 (BST2) expression on Human peripheral blood leucocyte populations. Human whole blood was stained with either FITC Mouse IgG2a, κ Isotype Control (Cat. No. 553456/554647; Left Plot) or FITC Mouse Anti-Human CD317 (BST2) antibody (Cat. No. 567999/568000; Right Plot). Erythrocytes were lysed with BD FACS Lysing™ Solution (Cat. No. 349202). The pseudocolor density plot showing the correlated expression of CD317 (BST2) [or Ig Isotype control staining] versus side light-scatter (SSC-A) signals was derived from gated events with the forward and side light-scatter characteristics of intact leucocyte populations. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software.
Multiparameter flow cytometric analysis of CD317 (BST2) expression on Rhesus peripheral blood leucocyte populations. Rhesus whole blood was stained with either FITC Mouse IgG2a, κ Isotype Control (Cat. No. 553456/554647; Left Plot) or FITC Mouse Anti-Human CD317 (BST2) antibody (Cat. No. 567999/568000; Right Plot). Erythrocytes were lysed with BD FACS Lysing™ Solution (Cat. No. 349202). The pseudocolor density plot showing the correlated expression of CD317 (BST2) [or Ig Isotype control staining] versus side light-scatter (SSC-A) signals was derived from gated events with the forward and side light-scatter characteristics of intact leucocyte populations. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software.
Product Details
Down Arrow Up Arrow


BD Pharmingen™
BST2; BST-2; bone marrow stromal antigen 2; HM1.24 antigen; Tetherin
Human (QC Testing), Rhesus, Cynomolgus, Baboon (Tested in Development)
Mouse BALB/c IgG2a, κ
Human KPC-32 Plasma Cell Line
Flow cytometry (Routinely Tested)
5 µl
VIII 80114
Aqueous buffered solution containing BSA and ≤0.09% sodium azide.
RUO


Preparation And Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions and unconjugated antibody and free dye were removed.

Recommended Assay Procedures

BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation).  When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells.   However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls.  It is strongly recommended that when using a reagent for the first time, users compare the spillover on cell and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.

Product Notices

  1. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
  2. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
  3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  4. This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1 × 10^6 cells in a 100-µl experimental sample (a test).
  5. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
  6. An isotype control should be used at the same concentration as the antibody of interest.
  7. Species cross-reactivity detected in product development may not have been confirmed on every format and/or application.
  8. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
567999 Rev. 1
Antibody Details
Down Arrow Up Arrow
Y129

The Y129 monoclonal antibody specifically binds to CD317 which is also known as Bone marrow stromal antigen 2 (BST2). CD317 is a type II transmembrane glycoprotein that belongs to the Tetherin family. CD317 is an interferon (IFN)-induced protein that is expressed on monocytes, granulocytes, dendritic cells, B lymphoblasts, plasma cells, T cells, natural killer (NK) cells, stromal cells and myeloma cells. CD317 is expressed by nonhematopoietic cells including cells within solid tumors derived from breast, lung and kidney. CD317 may be involved in the interactions between bone marrow stromal cells and lymphocytes. It is likewise known as Tetherin and reportedly blocks the release of some enveloped viruses by tethering virions to infected cell membranes. CD317 stimulates signaling by CD85g (ILT7) and may provide negative feedback for interferon (IFN) production by plasmacytoid dendritic cells during viral infections.

567999 Rev. 1
Format Details
Down Arrow Up Arrow
FITC
Fluorescein (FITC) is part of the BD blue family of dyes. This is a small organic fluorochrome with an excitation maximum (Ex Max) at 494-nm and an emission maximum (Em Max) at 518-nm. FITC is designed to be excited by the Blue laser (488-nm) and detected using an optical filter centered near 520 nm (e.g., a 530/30-nm bandpass filter). Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
altImg
FITC
Blue 488 nm
494 nm
518 nm
567999 Rev.1
Citations & References
Down Arrow Up Arrow
View product citations for antibody "567999" on CiteAb

Development References (11)

  1. Buckley CD, Halder S, Hardie D, et al. Report on antibodies submitted to the stromal cell section of HLDA8.. Cell Immunol. 236(1-2):29-41. (Immunogen). View Reference
  2. Gong S, Osei ES, Kaplan D, Chen YH, Meyerson H. CD317 is over-expressed in B-cell chronic lymphocytic leukemia, but not B-cell acute lymphoblastic leukemia.. Int J Clin Exp Pathol. 2015; 8(2):1613-21. (Biology). View Reference
  3. Goto T, Kennel SJ, Abe M, et al. A novel membrane antigen selectively expressed on terminally differentiated human B cells.. Blood. 1994; 84(6):1922-30. (Immunogen). View Reference
  4. Harada T, Ozaki S. Targeted therapy for HM1.24 (CD317) on multiple myeloma cells.. Biomed Res Int. 2014; 2014:965384. (Clone-specific: Functional assay, In vivo exacerbation, Radioimmunoassay). View Reference
  5. Mahauad-Fernandez WD, Okeoma CM. The role of BST-2/Tetherin in host protection and disease manifestation.. Immun Inflamm Dis. 2016; 4(1):4-23. (Biology). View Reference
  6. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.. Nature. 2008; 451(7177):425-30. (Biology). View Reference
  7. Serra-Moreno R, Jia B, Breed M, Alvarez X, Evans DT. Compensatory changes in the cytoplasmic tail of gp41 confer resistance to tetherin/BST-2 in a pathogenic nef-deleted SIV.. Cell Host Microbe. 2011; 9(1):46-57. (Clone-specific: Immunofluorescence). View Reference
  8. Staudinger M, Glorius P, Burger R, et al. The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells.. Blood Cancer J. 2014; 4:e219. (Biology). View Reference
  9. Van Damme N, Goff D, Katsura C, et al. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein.. Cell Host Microbe. 2008; 3(4):245-52. (Clone-specific: Flow cytometry). View Reference
  10. Vidal-Laliena M, Romero X, March S, Requena V, Petriz J, Engel P. Characterization of antibodies submitted to the B cell section of the 8th Human Leukocyte Differentiation Antigens Workshop by flow cytometry and immunohistochemistry. Cell Immunol. 2005; 236(1-2):6-16. (Clone-specific: Calcium Flux, Flow cytometry). View Reference
  11. Wiche Salinas TR, Gosselin A, Raymond Marchand L, et al. IL-17A reprograms intestinal epithelial cells to facilitate HIV-1 replication and outgrowth in CD4+ T cells.. iScience. 2021; 24(11):103225. (Clone-specific: Flow cytometry). View Reference
View All (11) View Less
567999 Rev. 1

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.